Skip to navigation Skip to content

Gilenya®: Information To Consider (video)


Part two of a two-part interview with Aaron Miller, MD, who discusses Gilenya®, an oral therapy for multiple sclerosis. Dr. Miller talks about who can take Gilenya®, cost and availability.

In 2018, the U.S. Food and Drug Administration approved the expansion of the use of the oral MS therapy Gilenya® (fingolimod, Novartis AG) to include the treatment of children and adolescents 10 years of age or older with relapsing MS.

To learn more about Gilenya® and other disease modifying treatment options, download the Consensus on Disease-Modifying Therapies, summary and medication guide.


© 2024 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.